-DOCSTART- -X- O
ABSTRACT -X- _ O
: -X- _ O
Middle -X- _ B-Patient
East -X- _ I-Patient
respiratory -X- _ I-Patient
syndrome -X- _ I-Patient
coronavirus -X- _ I-Patient
( -X- _ I-Patient
MERS-CoV -X- _ I-Patient
) -X- _ I-Patient
infection -X- _ I-Patient
in -X- _ I-Patient
humans -X- _ I-Patient
is -X- _ O
highly -X- _ O
lethal -X- _ O
, -X- _ O
with -X- _ O
a -X- _ O
fatality -X- _ O
rate -X- _ O
of -X- _ O
35 -X- _ O
% -X- _ O
. -X- _ O
New -X- _ O
prophylactic -X- _ O
and -X- _ O
therapeutic -X- _ O
strategies -X- _ O
to -X- _ O
combat -X- _ O
human -X- _ O
infections -X- _ O
are -X- _ O
urgently -X- _ O
needed. -X- _ O
We -X- _ O
isolated -X- _ O
a -X- _ O
fully -X- _ B-Intervention
human -X- _ I-Intervention
neutralizing -X- _ I-Intervention
antibody -X- _ I-Intervention
, -X- _ I-Intervention
MCA1 -X- _ I-Intervention
, -X- _ O
from -X- _ O
a -X- _ O
human -X- _ O
survivor. -X- _ O
The -X- _ O
antibody -X- _ B-Outcome
recognizes -X- _ I-Outcome
the -X- _ I-Outcome
receptor-binding -X- _ I-Outcome
domain -X- _ I-Outcome
of -X- _ I-Outcome
MERS-CoV -X- _ I-Outcome
S -X- _ I-Outcome
glycoprotein -X- _ I-Outcome
and -X- _ I-Outcome
interferes -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
interaction -X- _ I-Outcome
between -X- _ I-Outcome
viral -X- _ I-Outcome
S -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
human -X- _ I-Outcome
cellular -X- _ I-Outcome
receptor -X- _ I-Outcome
human -X- _ I-Outcome
dipeptidyl -X- _ I-Outcome
peptidase -X- _ I-Outcome
4 -X- _ I-Outcome
( -X- _ I-Outcome
DPP4 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
To -X- _ O
our -X- _ O
knowledge -X- _ O
, -X- _ O
this -X- _ O
study -X- _ O
is -X- _ O
the -X- _ O
first -X- _ O
to -X- _ O
report -X- _ O
a -X- _ O
human -X- _ B-Outcome
neutralizing -X- _ I-Outcome
monoclonal -X- _ I-Outcome
antibody -X- _ I-Outcome
that -X- _ I-Outcome
completely -X- _ I-Outcome
inhibits -X- _ I-Outcome
MERS-CoV -X- _ I-Outcome
replication -X- _ I-Outcome
in -X- _ I-Outcome
common -X- _ I-Outcome
marmosets. -X- _ I-Outcome
Monotherapy -X- _ O
with -X- _ O
MCA1 -X- _ O
represents -X- _ O
a -X- _ O
potential -X- _ O
alternative -X- _ O
treatment -X- _ O
for -X- _ O
human -X- _ O
infections -X- _ O
with -X- _ O
MERS-CoV -X- _ O
worthy -X- _ O
of -X- _ O
evaluation -X- _ O
in -X- _ O
clinical -X- _ O
settings -X- _ O
. -X- _ O

